Comparative Pharmacology
Head-to-head clinical analysis: AVC versus SULFA TRIPLE 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVC versus SULFA TRIPLE 2.
AVC vs SULFA-TRIPLE #2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVC (sulfanilamide) is a sulfonamide antibiotic that inhibits bacterial dihydrofolate synthesis by competing with para-aminobenzoic acid (PABA), thereby blocking folic acid production and bacterial growth.
The sulfonamides (sulfamethazine, sulfathiazole, sulfamerazine) act as competitive inhibitors of para-aminobenzoic acid (PABA) utilization in bacterial dihydrofolate synthesis, thereby inhibiting folic acid synthesis and bacterial growth.
1 applicatorful (approximately 5 g of 0.1% cream) intravaginally once daily at bedtime for 7 days.
2 tablets orally every 4 hours initially, then 2 tablets every 6 hours thereafter. Each tablet contains 167 mg sulfadiazine, 167 mg sulfamerazine, and 167 mg sulfamethazine (total sulfonamide 500 mg per tablet).
None Documented
None Documented
3-5 hours; prolonged in renal impairment (up to 12 hours).
Sulfadiazine: 10-16 hours; Sulfamerazine: 15-24 hours; Sulfamethazine: 12-24 hours. The combined half-life is approximately 15-20 hours in patients with normal renal function, requiring dosing every 12-24 hours.
Renal: 30-50% unchanged; biliary/fecal: 10-20% as metabolites.
Renal (approximately 70-80% as unchanged sulfonamides via glomerular filtration and tubular secretion); biliary/fecal (approximately 20-30% as metabolites).
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)